Apramycin is a unique aminoglycoside with a dissociation of antibacterial activity and 29 ototoxicity. We assessed the antibacterial efficacy of apramycin in two murine models of 30 infection: Mycobacterium tuberculosis aerosol infection and Staphlyococcus aureus septicaemia. 31
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Emerging resistance globally threatens the efficacy of antibiotics (1), arguably one of the most 36 significant achievements in human medicine. The prospects for novel classes of antibiotics are 37 scarce (2) and there is an urgent need to improve available antibiotic compounds (3). 38
The first aminoglycoside, streptomycin, was introduced almost 70 years ago and since then 39 numerous aminoglycosides have been isolated, and new derivatives have been synthesized (4). 40
Aminoglycosides have broad-spectrum activity and are used for treatment of serious life-41 threatening infections, including tuberculosis (5). As with all antibiotics, resistance to 42 aminoglycosides has evolved in the past decades and significantly impairs the clinical utility of 43 these compounds (6). Resistance to aminoglycosides is conferred primarily by aminoglycoside-44 modifying enzymes, which inactivate these compounds by various modifications of their NH 2 or 45 OH substituents (7). In addition, methyltransferases that modify bacterial rRNA, the molecular 46 target of aminoglycosides, confer high-level resistance to all clinically used aminoglycosides (8,  47 for review 9), including the most recently developed plazomicin, a semi-synthetic 48 aminoglycoside that has recently completed phase II clinical trials for complicated urinary tract 49 infections (10, 11) . 50
Apramycin is a structurally unique aminoglycoside, characterized by a bicyclic sugar moiety and 51 a 4-monosubstituted 2-deoxystreptamine ring (12). In-vitro apramycin shows broad-range 52 antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria 53
including Pseudomonas aeruginosa (13, 14). As a result of its unique structure, apramycin is not 54 inactivated by most of the known aminoglycoside-modifying enzymes (14), including N-55
acetlytransferases (AAC), O-nucleotidyltransferases (ANT) and O-phosphortransferases (APH). 56
In addition, apramycin has been found to be the only aminoglycoside active against producers of 57 rRNA methylases (11). Apramycin also shows high antimycobacterial activity in-vitro (14), 58 The clinical use of aminoglycosides is limited by their toxicity, in particular ototoxicity. The 65 ability of these compounds to cause irreversible hearing damage affects ~20% of patients 66 following brief courses of treatment and more than 90% of patients after long-term regimens (17, 67 18) . Aminoglycoside ototoxicity is linked to the destruction of the sensory cells of the inner ear 68 and consistently has been associated with both natural and semi-synthetic aminoglycosides (17) . 69
However, we have recently made the surprising observation that apramycin shows a unique 70 dissociation of antibacterial activity and ototoxicity, conferring it a low ototoxic potential (14). 
